{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:52:16Z","timestamp":1787007136845,"version":"build-2736575974"},"reference-count":78,"publisher":"Informa UK Limited","issue":"7","funder":[{"name":"funded"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2021,7,3]]},"DOI":"10.1080\/13543784.2021.1928636","type":"journal-article","created":{"date-parts":[[2021,5,9]],"date-time":"2021-05-09T14:50:49Z","timestamp":1620571849000},"page":"759-772","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":15,"title":["Targeted therapies for gallbladder cancer: an overview of agents in preclinical and clinical development"],"prefix":"10.1080","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4866-4864","authenticated-orcid":false,"given":"Stefania","family":"De Lorenzo","sequence":"first","affiliation":[{"name":"Azienda USL Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9302-6896","authenticated-orcid":false,"given":"Ingrid","family":"Garajova","sequence":"additional","affiliation":[{"name":"University Hospital of Parma","place":["Parma, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3800-5678","authenticated-orcid":false,"given":"Bernardo","family":"Stefanini","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria Di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8350-1155","authenticated-orcid":false,"given":"Francesco","family":"Tovoli","sequence":"additional","affiliation":[{"name":"IRCCS Azienda Ospedaliero-Universitaria Di Bologna","place":["Bologna, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,5,17]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21387"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v23.i22.3978"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2016-000152"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S37357"},{"key":"e_1_3_4_7_1","first-page":"1532835","article-title":"Gallbladder Carcinoma in the United States: a Population Based Clinical Outcomes Study Involving 22,343 Patients from the Surveillance, Epidemiology, and End Result Database (1973-2013)","volume":"2017","author":"Lau CSM","year":"2017","unstructured":"Lau CSM, Zywot A, Mahendraraj K, et al. Gallbladder Carcinoma in the United States: a Population Based Clinical Outcomes Study Involving 22,343 Patients from the Surveillance, Epidemiology, and End Result Database (1973-2013). HPB Surg World J Hepatic Pancreat Biliary Surg. 2017;2017:1532835.","journal-title":"HPB Surg World J Hepatic Pancreat Biliary Surg"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a058597"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.annonc.a010676"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012543223020"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1023\/B:DRUG.0000011797.09549.53"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603334"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604628"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.5009\/gnl.2013.7.5.594"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz402"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2019.0270"},{"key":"e_1_3_4_18_1","first-page":"318","article-title":"Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: study protocol for a randomized controlled multicenter phase II\/III study","volume":"51","author":"Phelip J-M","year":"2019","unstructured":"Phelip J-M, Edeline J, Blanc J-F, et al. Modified FOLFIRINOX versus CisGem first-line chemotherapy for locally advanced non resectable or metastatic biliary tract cancer (AMEBICA)-PRODIGE 38: study protocol for a randomized controlled multicenter phase II\/III study. Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver. 2019;51:318\u2013320.","journal-title":"Dig Liver Dis Off J Ital Soc Gastroenterol Ital Assoc Study Liver"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00027-9"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1159\/000226214"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2106-0"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2016.1191670"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyv148"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0698-9"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0874"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2013.11.001"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0245"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-1318"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7819-9-131"},{"issue":"2","key":"e_1_3_4_30_1","first-page":"42","article-title":"Overexpression of the HER2\/neu Gene: a New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer","volume":"7","author":"Roa I","year":"2014","unstructured":"Roa I, De Toro G, Schalper K, et al. Overexpression of the HER2\/neu Gene: a New Therapeutic Possibility for Patients With Advanced Gallbladder Cancer. Gastrointest Cancer Res GCR. 2014;7(2):42\u201348.","journal-title":"Gastrointest Cancer Res GCR"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.6313"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-015-0155-z"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30254"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206007"},{"key":"e_1_3_4_35_1","unstructured":"Pertuzumab + trastuzumab for HER2-positive metastatic biliary cancer: preliminary data from MyPathway. | journal of Clinical Oncology [Internet]. [cited 2021 Mar 2]. Available from: https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2017.35.4_suppl.402."},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature25475"},{"key":"e_1_3_4_37_1","unstructured":"Efficacy and safety of varlitinib a reversible pan-HER tyrosine kinase inhibitor in combination with platinum-based regimens in biliary tract cancers: a pooled analysis from three phase I studies. | journal of Clinical Oncology [Internet]. [cited 2021 Mar 2]. Available from: https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2019.37.4_suppl.331."},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-5223-7"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-0927-7"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.3579"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70301-1"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.801"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0253"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70212-8"},{"issue":"49","key":"e_1_3_4_45_1","first-page":"3806","article-title":"Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study","volume":"2013","author":"Rubovszky G","year":"1990","unstructured":"Rubovszky G, L\u00e1ng I, Ganofszky E, et al. Cetuximab, gemcitabine and capecitabine in patients with inoperable biliary tract cancer: a phase 2 study. Eur J Cancer Oxf Engl. 1990;2013(49):3806\u20133812.","journal-title":"Eur J Cancer Oxf Engl"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds008"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt416"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510280610"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07365-4"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31872"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32964"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00139-4"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0708857"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(08)70285-7"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.09.013"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605458"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601488"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.52.5.706"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-004-1046-9"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.3800204"},{"key":"e_1_3_4_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature04304"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.9473"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-018-0600-2"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0523-5"},{"issue":"130","key":"e_1_3_4_65_1","first-page":"219","article-title":"Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer","volume":"2020","author":"Kim RD","year":"1990","unstructured":"Kim RD, McDonough S, El-Khoueiry AB, et al. Randomised phase II trial (SWOG S1310) of single agent MEK inhibitor trametinib Versus 5-fluorouracil or capecitabine in refractory advanced biliary cancer. Eur J Cancer Oxf Engl. 1990;2020(130):219\u2013227.","journal-title":"Eur J Cancer Oxf Engl"},{"key":"e_1_3_4_66_1","unstructured":"525 Safety and efficacy of pembrolizumab (MK-3475) in patients (pts) with advanced biliary tract cancer: interim results of KEYNOTE-028 - European Journal of Cancer [Internet]. [cited 2021 Mar 9]. Available from: https:\/\/www.ejcancer.com\/article\/S0959-8049(16)30326-4\/pdf"},{"key":"e_1_3_4_67_1","unstructured":"Pembrolizumab (pembro) for advanced biliary adenocarcinoma: results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies. | journal of Clinical Oncology [Internet]. [cited 2021 Mar 9]. Available from: https:\/\/ascopubs.org\/doi\/abs\/10.1200\/JCO.2019.37.15_suppl.4079."},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02105"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13071569"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0044"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.0930"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(19)30086-X"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.4_suppl.387"},{"key":"e_1_3_4_75_1","first-page":"8(2):e000664","article-title":"Bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort","author":"Cho BC","year":"2020","unstructured":"Cho BC, Daste A, Ravaud A, et al. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort. J Immunother Cancer. 2020;8(2):e000664.","journal-title":"J Immunother Cancer"},{"key":"e_1_3_4_76_1","first-page":"8(2):e001395","article-title":"Bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with human papillomavirus-associated malignancies","author":"Strauss J","year":"2020","unstructured":"Strauss J, Gatti-Mays ME, Cho BC, et al. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-\u03b2 and PD-L1, in patients with human papillomavirus-associated malignancies. J Immunother Cancer. 2020;8(2):e001395.","journal-title":"J Immunother Cancer"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-000564"},{"key":"e_1_3_4_78_1","unstructured":"Merck Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment | merck [Internet]. [cited 2021 May 2]. Available from: https:\/\/www.merckgroup.com\/en\/news\/bintrafusp-topline-data-biliary-tract-cancer-16-03-2021.html."},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1063-5"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.27224"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2021.1928636","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T03:47:19Z","timestamp":1772768839000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2021.1928636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,17]]},"references-count":78,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7,3]]}},"alternative-id":["10.1080\/13543784.2021.1928636"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2021.1928636","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,17]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-03-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}